Rituximab news

Rituxan co-promotion in Japan ends Sept 3, 2026. One partner will cease sales on sell-out; the other assumes sole sales and medical information from Sept 4. Transition to ensure stable supply.

Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.

Rituxan gains approval for treating autoimmune hemolytic anemia, targeting B cells to reduce autoantibodies. Effective for warm AIHA, CAD, and PCH, offering an alternative to steroids.

The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.

Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.

Jaypirca reduced disease progression risk by 80% in CLL/SLL patients, showing promising safety and efficacy in a Phase 3 trial, with fewer adverse events compared to chemoimmunotherapy.

EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.

EPKINLY + R² shows superior progression-free survival and response rates in Phase 3 trial for relapsed follicular lymphoma, with a consistent safety profile.